Kala Pharmaceuticals, Inc.'s (KALA) CEO Mark Iwicki on Q4 2018 Results - Earnings Call Transcript [Seeking Alpha]
Kala Pharmaceuticals, Inc. (KALA)
Last kala pharmaceuticals, inc. earnings: 2/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.kalarx.com
Company Research
Source: Seeking Alpha
Kala Pharmaceuticals, Inc.'s (KALA) CEO Mark Iwicki on Q4 2018 Results - Earnings Call Transcript Kala Pharmaceuticals, Inc. (NASDAQ: KALA Company Participants Mary Reumuth - CFO Mark Iwicki - Chairman, President, CEO Kim Brazzell - Chief Medical Officer Todd Bazemore - COO Hongming Chen - Chief Scientific Officer Conference Call Participants David Maris - Wells Fargo Liana Moussatos - Wedbush Securities Yi Chen - H.C. Wainwright Operator Good day, and welcome to Kala Pharmaceuticals Fourth Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, a Q&A session will be held. And as a reminder, this call is being recorded. I would now like to turn the call over to Mary Reumuth, Chief Financial Officer for Kala Pharmaceuticals. Please proceed. Thank you, Operator, and thank you all for participating in today's call. Joining me from the company are Mark Iwicki, Chairman, President, and Chief Executive Officer
Show less
Read more
Impact Snapshot
Event Time:
KALA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KALA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KALA alerts
High impacting Kala Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
KALA
News
- KALA BIO, Inc. (NASDAQ: KALA) had its price target lowered by analysts at HC Wainwright from $22.00 to $21.00. They now have a "buy" rating on the stock.MarketBeat
- KALA BIO, Inc. (NASDAQ: KALA) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $15.00 price target on the stock.MarketBeat
- KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewswire
- KALA BIO to Present at TD Cowen 44th Annual Healthcare ConferenceGlobeNewswire
- KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewswire
KALA
Earnings
- 3/29/24 - Beat
KALA
Sec Filings
- 4/19/24 - Form PRE
- 3/29/24 - Form 424B5
- 3/29/24 - Form S-8
- KALA's page on the SEC website